Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
doi:10.1016/j.cca.2008.12.027
Status Still investigational Retatrutide has Phase 3 data but no FDA-approved prescribing label yet
Patients must be able to participate in digital consultations, adhere to prescribed dosing schedules, and engage with ongoing monitoring protocols
Contact PlexusDx immediately
Injection-site reactions (515%): Mild redness/itching/lumps
A thorough riskbenefit assessment is essential before considering use
US$ 28.60
US$ 29.61
US$ 28.08
US$ 26.27
US$ 29.36
US$ 28.90
